U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. CVM GFI #144 (VICH GL27) Pre-Approval Information for Registration of New Veterinary Medicinal Products for Food-Producing Animals with Respect to Antimicrobial Resistance
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

CVM GFI #144 (VICH GL27) Pre-Approval Information for Registration of New Veterinary Medicinal Products for Food-Producing Animals with Respect to Antimicrobial Resistance April 2004

Final
Docket Number:
FDA-2003-D-0152
Issued by:
Guidance Issuing Office
Center for Veterinary Medicine

The use of antimicrobial agents is likely to lead to selection of resistance whether administered to humans, animals or plants. Zoonotic organisms such as non-typhoid Salmonellae, Campylobacter spp. and enterohaemorrhagic E. coli (e.g., O157) can, by definition, be transferred to humans from animals. Therefore, it stands to reason that resistant zoonotic organisms can also be transferred to humans. The transfer of antimicrobial-resistant non-zoonotic bacteria or their genetic material from animals to humans via the food chain is also possible. However, data demonstrating the magnitude and importance of such transfer and whether such transfer occurs via consumption of contaminated meat or via contamination of water or vegetables by animal excreta are limited. Humans are also a potential reservoir of antimicrobial-resistant microorganisms.

The extent to which food-producing animals contribute to human exposure to antimicrobial-resistant microorganisms is difficult to quantify. However, when evaluating the safety of antimicrobial products for use in food-producing animals, regulatory authorities should consider the potential for such products to select for resistant bacteria. Therefore, guidance is needed for drug sponsors on the type of information that should be provided to the regulatory authorities. This information should help to characterize the potential for the use of the product to select for antimicrobial-resistant bacteria of human health concern. The information provided should be used as part of an overall assessment of the potential impact of the product on human health.


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2003-D-0152.

Questions?

Back to Top